Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Siemens, NKF enter strategic alliance, 5/14

May 2014—Siemens Healthcare and the National Kidney Foundation entered into a strategic alliance to increase awareness of the importance of albumin-to-creatinine ratio testing in high-risk individuals, with the goal of improving diagnosis and identifying kidney disease early in its course. Siemens and NKF will also help put the new clinical recommendations into practice.

Bone marrow tissue stain, 5/14

May 2014—Dako added the Jenner-Wright Giemsa stain to its Artisan Link portfolio of automated stains. The stain is designed to provide clear differentiation and detail of the hematopoietic cells in bone marrow tissue samples for the diagnosis of cancer, aplastic anemia, and myelofibrosis.

Hsp70 ELISA kit, 5/14

May 2014—Enzo Life Sciences now offers the Amp’d HSP70 High Sensitivity ELISA Kit for detecting both baseline and upregulated levels of Hsp70 (Hsp72).

FISH upgrades for improved virtual analysis, 5/14

May 2014—Clarient Diagnostic Service, a GE Healthcare company, upgraded its fluorescence in situ hybridization technologies to improve virtual analysis of test results for leukemia, lymphoma, myelodysplastic syndrome, and myeloma.

Coulter Counter, 5/14

May 2014—The Multisizer 4e Coulter Counter from Beckman Coulter Life Sciences has a 10-µm aperture for obtaining accurate count, size, and mass distribution for particles and cells ranging from 0.2 to 1,600 µm. Digital pulse processing provides high-resolution analysis in up to 400 channels.

Distribution agreement

May 2014—Copan Diagnostics announced an agreement with Thermo Fisher Scientific to distribute the Copan WASP, a walk-away specimen processor, in the United States.

Insight Genetics and VICC partnership, 5/14

May 2014—Insight Genetics is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to identify genetic markers that will help select the targeted therapeutics most effective for each triple-negative breast cancer patient.

Handheld pipette

May 2014—Eppendorf’s Repeater M4 is a handheld pipette that works with nine sizes of the company’s Combitips advanced.